LGALS3BP and neoplasm: Finally, in 2015 Piccolo et al. [80] confirmed and extended these findings, demonstrating that LGALS3BP expression in primary tumor tissue correlated with a better disease-free and overall survival outcome, whereas low LGALS3BP expression correlated with a poorer survival outcome; moreover they showed that LGALS3BP silenced human CRC cells by RNAi formed large tumors when implanted in nude mice and that intra-tumor delivery of human recombinant LGALS3BP induced regression of established CRC xenografts [80].